Related Experiment Video

Updated: Nov 25, 2025

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

779

GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets

Nada H Hussein1, Nada S Amin1, Hend M El Tayebi1

  • 1Molecular Pharmacology Research Group, Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.

Frontiers in Oncology
|December 21, 2020
PubMed

Insights

Glycosylphosphatidylinositol-Anchored Proteins (GPI-APs) are crucial in cancer's immune evasion. Understanding these membrane proteins offers new avenues for early cancer diagnosis and targeted immune therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Cancer presents significant diagnostic and therapeutic challenges due to late detection and harsh conventional treatments.
  • Carcinogenesis involves key cellular steps known as cancer hallmarks, often initiated by receptor-ligand interactions.
  • Understanding cell membrane topology is critical for deciphering cancer progression.

Purpose of the Study:

  • To review the role of Glycosylphosphatidylinositol-Anchored Proteins (GPI-APs) in cancer.
  • To highlight how GPI-APs contribute to tumor cells evading immune surveillance.
  • To explore the future applications of GPI-APs in cancer diagnosis and immune-targeted therapy.

Main Methods:

  • This review synthesizes current research on GPI-APs in cancer.
  • Focuses on the function of GPI-APs in tumor cell immune evasion.
  • Examines the potential of GPI-APs as biomarkers and therapeutic targets.

Main Results:

  • GPI-APs are implicated in cancer progression and immune evasion mechanisms.
  • Specific GPI-APs are overexpressed or altered in various tumor types.
  • These proteins present opportunities for novel diagnostic and therapeutic strategies.

Conclusions:

  • GPI-APs are vital players in cancer biology, particularly in immune evasion.
  • Targeting GPI-APs holds promise for developing innovative early diagnostic tools.
  • Further research into GPI-APs can lead to effective immune-targeted cancer therapies.
Keywords:
cancerglycosylphosphatidylinositolglycosylphosphatidylinositol-anchored proteinimmunologyimmunotherapy

More Related Videos

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.7K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.1K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
880
GPI Anchoring of Proteins in the ER Membrane01:29

GPI Anchoring of Proteins in the ER Membrane

GPI-anchoring is a post-translational, reversible protein modification that is ubiquitous in eukaryotes. Such proteins are primarily present on the exoplasmic leaflet of the plasma membrane.
GPI-anchor structure
A sequence of 11 enzymatic reactions results in the synthesis of the complete GPI anchor consisting of a hydrophobic and a hydrophilic portion. The hydrophobic portion comprises phosphatidylinositol, while the hydrophilic part comprises polar groups like phosphoethanolamine,...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
13.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.9K